BD Announces Enrollment in Post-Market Studies of the WavelinQ™ Arteriovenous Endovascular Fistula
Share this article Share this article FRANKLIN LAKES, N.J., April 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that enrollment has begun and the first patients have been treated in the post-market surveillance study, CONNECT-AV. CONNECT-AV is a prospective, single-arm, open-label study that will follow patients treated with the WavelinQ TM EndoAVF System for 24 months. WavelinQ EndoAVF System The studys d...
United States Butler Memorial Hospital Panagiotism Kitrou Brandon Repko Troy Kirkpatrick Kristenm Stewart
Source: prnewswire.com